看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
) Z2 p- O9 o+ I4 c5 \
3 E+ Y4 t% M e/ z
. {4 { ^3 i1 E& CCurrently available feasibility data for possible combination strategies.
6 }. R% q5 T) T8 C$ r————————————————————————————————
; v' l) ?% _8 J; P) w( qCombination Feasibility according to preliminary data - w- b- [" r6 E; I9 W' m3 ]
——————————————————————————————————
, `+ r; u0 K8 }3 K8 i3 yBevacizumab + sorafenib Yes, reduced dose
z, _; c9 F! _6 \; KBevacizumab + sunitinib† No
/ @+ v1 z* k& pBevacizumab + temsirolimus Yes
4 J7 E8 {% L) ]7 c! E3 VBevacizumab + everolimus Yes
, W$ V q! w) t& T5 w( f0 M$ ^Sorafenib + sunitinib ? 8 s4 }( ` |( m% ]; k, S( Z
Sorafenib + temsirolimus Yes, reduced dose - K9 F! |7 H8 ~# C5 t8 a
Sorafenib + everolimus Yes, reduced dose
/ a9 M9 D ^# w9 iSunitinib + temsirolimus† No
$ E \; H/ R; A$ }# A1 pSunitinib + everolimus ?
8 V) k# M M! i* fTemsirolimus + everolimus ? 3 C9 |1 [; E9 K9 l% @
————————————————————. v& q, @: @) s3 [2 w/ c
†Led to US FDA warning.
0 e: i& a. q# C8 X, Z$ [, I?: As yet unattempted combination.
- G6 ^2 h4 V) y1 a) l5 N3 D |